Arzoxifene

DB06249ApprovedWithdrawnSmall molecule

Investigated for use/treatment in breast cancer, osteoporosis, and endometrial cancer.

Mechanism: Arzoxifene is a selective estrogen receptor modulator (SERM) which antagonizes estrogen in mammary and uterine tissue, but acts as an estrogen receptor agonist in bone tissue. Arzoxifene reduces bone loss and risk of osteoperosis and decreases serum cholesterol.
Curator reviewed
Primary indication: Investigated for use/treatment in breast cancer, osteoporosis, and endometrial cancer.Curator reviewed
Formula / weight: C₂₈H₂₉NO₄S · 475.6 g/mol (avg)
Code names: LY353381

Resolves to

Compound

Structure

InChIKeyMCGDSOGUHLTADD-UHFFFAOYSA-NSMILESCOC1=CC=C(C=C1)C1=C(OC2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2

Targets

What you can answer from here — as of September 13, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Arzoxifene, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.